Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO
SANGAMO THERAPEUTICS
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
7000 Marina Blvd, Brisbane, California 94005, US HQ
1995 Founded
266 Employees
Public company Type
SGMO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 7000 Marina Blvd, Brisbane, California 94005, US
- Founded
- 1995
- Employees
- 266
- Programs
- 25
- Drugs
- 14
- Patents
- 192
SANGAMO THERAPEUTICS pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
SANGAMO THERAPEUTICS drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
busulfan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
plerixafor
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: C-X-C chemokine receptor type 4.
- Target
- C-X-C chemokine receptor type 4
- Mechanism
- C-X-C chemokine receptor type 4 partial agonist
-
Development asset linked to SANGAMO THERAPEUTICS in public FDA and regional records.